Sign In
Buy VATE
Elev8 Brands Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$2.18 |
| EPS actual | -$1.29 |
| EPS Surprise | 40.94% |
| Revenue estimate | 251.7M |
| Revenue actual | 364.8M |
| Revenue Surprise | 44.93% |
| Release date | Mar 26, 2026 |
| EPS estimate | -$2.18 |
| EPS actual | -$0.580 |
| EPS Surprise | 73.45% |
| Revenue estimate | 251.7M |
| Revenue actual | 382.7M |
| Revenue Surprise | 52.05% |
| Release date | Nov 12, 2025 |
| EPS estimate | - |
| EPS actual | -$0.710 |
| Revenue estimate | - |
| Revenue actual | 347.1M |
| Release date | Aug 05, 2025 |
| EPS estimate | - |
| EPS actual | -$1.67 |
| Revenue estimate | - |
| Revenue actual | 242M |
Last 4 Quarters for Elev8 Brands
Below you can see how VATE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $5.76 |
| EPS estimate | - |
| EPS actual | -$1.67 |
| Date | Price |
|---|---|
| Jul 30, 2025 | $5.86 |
| Jul 31, 2025 | $5.66 |
| Aug 01, 2025 | $5.27 |
| Aug 04, 2025 | $5.36 |
| Aug 05, 2025 | $5.76 |
| Aug 06, 2025 | $5.68 |
| Aug 07, 2025 | $4.55 |
| Aug 08, 2025 | $5.15 |
| Aug 11, 2025 | $4.74 |
| 4 days before | -1.71% |
| 4 days after | -17.71% |
| On release day | -1.39% |
| Change in period | -19.11% |
| Release date | Nov 12, 2025 |
| Price on release | $5.70 |
| EPS estimate | - |
| EPS actual | -$0.710 |
| Date | Price |
|---|---|
| Nov 06, 2025 | $5.87 |
| Nov 07, 2025 | $5.68 |
| Nov 10, 2025 | $5.50 |
| Nov 11, 2025 | $5.65 |
| Nov 12, 2025 | $5.70 |
| Nov 13, 2025 | $5.60 |
| Nov 14, 2025 | $5.15 |
| Nov 17, 2025 | $4.77 |
| Nov 18, 2025 | $5.12 |
| 4 days before | -2.98% |
| 4 days after | -10.10% |
| On release day | -1.67% |
| Change in period | -12.78% |
| Release date | Mar 26, 2026 |
| Price on release | $4.03 |
| EPS estimate | -$2.18 |
| EPS actual | -$0.580 |
| EPS surprise | 73.45% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $4.00 |
| Mar 23, 2026 | $4.03 |
| Mar 24, 2026 | $4.21 |
| Mar 25, 2026 | $4.08 |
| Mar 26, 2026 | $4.03 |
| Mar 27, 2026 | $4.59 |
| Mar 30, 2026 | $5.50 |
| Mar 31, 2026 | $5.68 |
| Apr 01, 2026 | $6.83 |
| 4 days before | 0.750% |
| 4 days after | 69.48% |
| On release day | 13.90% |
| Change in period | 70.75% |
| Release date | May 14, 2026 |
| Price on release | $11.68 |
| EPS estimate | -$2.18 |
| EPS actual | -$1.29 |
| EPS surprise | 40.94% |
| Date | Price |
|---|---|
| May 08, 2026 | $11.73 |
| May 11, 2026 | $12.45 |
| May 12, 2026 | $12.40 |
| May 13, 2026 | $11.76 |
| May 14, 2026 | $11.68 |
| May 15, 2026 | $10.66 |
| May 18, 2026 | $10.89 |
| May 19, 2026 | $12.08 |
| May 20, 2026 | $13.16 |
| 4 days before | -0.426% |
| 4 days after | 12.67% |
| On release day | -8.73% |
| Change in period | 12.19% |
Elev8 Brands Earnings Call Transcript Summary of Q1 2026
INNOVATE reported Q1 2026 consolidated revenue of $364.8M (up 33% YoY) and adjusted EBITDA of $19.7M (up from $7.2M a year ago). Infrastructure (DBM Global) was the primary growth driver: Infrastructure revenue rose ~35% to $357.9M, adjusted EBITDA increased to $23M, and adjusted backlog remained $1.8B with strong pipeline momentum in technology-related projects (data centers, chipmakers, AI infrastructure). Life Sciences showed mixed results: MediBeacon advanced regulatory, clinical and commercial milestones (CE mark, multiple IDE approvals, wearable TGFR sensor ready for study) while R2 revenue declined YoY to $1.6M but maintained a backlog of ~160 systems (~$2M) and is seeking external capital. Spectrum revenue and EBITDA declined (Q1 revenue $5.3M, adjusted EBITDA $0.7M) due to softer advertising demand and network cancellations, though management highlighted regulatory tailwinds (LPT filing, Class A upgrades) and potential 5G broadcast conversion advocacy. Net loss narrowed to $17.2M ($1.29/sh) from $24.8M a year ago. Cash was $134.6M (March 31), total debt was $699M (up slightly driven by PIK interest). Management is pursuing capital-structure alternatives with lenders. Key near-term investor considerations: DBMG’s strong backlog and project pipeline, MediBeacon’s regulatory/clinical progress and capital needs at R2, Spectrum’s turnaround hinging on regulatory outcomes and demand recovery, and overall balance-sheet/capital-structure risk given ~ $699M debt and ongoing work with lenders.
